tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Nephritis, Hereditary D009394 1 associated lipids
Skin Diseases, Papulosquamous D017444 2 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Collagen Diseases D003095 2 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Anemia, Refractory D000753 3 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Tongue Diseases D014060 2 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Discitis D015299 2 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Pityriasis Lichenoides D017514 2 associated lipids
Histiocytosis D015614 2 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Rupture D012421 2 associated lipids
Lichen Nitidus D017513 1 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Porokeratosis D017499 1 associated lipids
Dermatitis, Perioral D019557 4 associated lipids
Scleritis D015423 3 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Intertrigo D007402 1 associated lipids
Impetigo D007169 3 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Pterygium D011625 3 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Mucinoses D017520 2 associated lipids
Carcinoma, Merkel Cell D015266 2 associated lipids
Nocturia D053158 1 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Malacoplakia D008287 1 associated lipids
Myelitis D009187 1 associated lipids
Erythroplasia D004919 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Hutchinson's Melanotic Freckle D018327 2 associated lipids
Lacerations D022125 1 associated lipids
Trauma, Nervous System D020196 2 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Neuroaspergillosis D020953 2 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Arm Injuries D001134 1 associated lipids
Lentigo D007911 1 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Poxviridae Infections D011213 1 associated lipids
Seminoma D018239 2 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brachial Plexus Neuritis D020968 2 associated lipids
Lymphomatoid Granulomatosis D008230 2 associated lipids
Dysuria D053159 1 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Mite Infestations D008924 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Sleep Apnea, Central D020182 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Digestive System Diseases D004066 3 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Retrognathia D063173 1 associated lipids
Leg Injuries D007869 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Granulomatosis, Orofacial D051261 2 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Pruritus Ani D011538 2 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Dumont FJ et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. 1990 J. Immunol. pmid:1688572
Woo J et al. Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. 1990 Clin. Exp. Immunol. pmid:1689226
Dumont FJ et al. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. 1990 J. Immunol. pmid:1689353
Brown Z and Neild GH FK-506 and haemolytic uraemic syndrome. 1990 Lancet pmid:1689442
Thomas J et al. The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. 1990 Transplantation pmid:1689518
Vathsala A et al. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. 1990 Transplantation pmid:1689520
Yamamoto K et al. Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506. 1990 Immunology pmid:1689694
Thomson AW Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. 1990 Transplant. Proc. pmid:1689883
Zeevi A et al. Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689884
Morris RE et al. Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. 1990 Transplant. Proc. pmid:1689885
Todo S et al. Early trials with FK 506 as primary treatment in liver transplantation. 1990 Transplant. Proc. pmid:1689886
Murase N et al. Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. 1990 Transplant. Proc. pmid:1689906
Hoffman AL et al. The effect of FK 506 on small intestine allotransplantation in the rat. 1990 Transplant. Proc. pmid:1689907
Lee KK et al. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. 1990 Transplant. Proc. pmid:1689908
Ueda Y et al. Induction of graft acceptance after dog kidney or liver transplantation. 1990 Transplant. Proc. pmid:1689909
Ohara K et al. Toxicologic evaluation of FK 506. 1990 Transplant. Proc. pmid:1689910
Nalesnik MA et al. The effect of FK 506 and CyA on the Lewis rat renal ischemia model. 1990 Transplant. Proc. pmid:1689911
Francavilla A et al. FK 506 as a growth control factor. 1990 Transplant. Proc. pmid:1689912
Mazzaferro V et al. Studies of the hepatotrophic qualities of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689913
Kay JE et al. The mechanism of action of FK 506. 1990 Transplant. Proc. pmid:1689914
Suzuki N et al. Effects of a novel immunosuppressive agent, FK506, on human B cell activation. 1990 Clin. Exp. Immunol. pmid:1690097
McCauley J et al. FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. 1990 Lancet pmid:1690326
Hoffman AL et al. The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. 1990 Transplantation pmid:1690469
Woo J et al. The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. 1990 Scand. J. Immunol. pmid:1690915
Tropschug M et al. Isolation and sequence of an FK506-binding protein from N. crassa which catalyses protein folding. 1990 Nature pmid:1696687
Randall T New antirejection drugs anticipated. 1990 JAMA pmid:1696999
Metcalfe S et al. FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. 1990 Transplant. Proc. pmid:1697107
Morris RE et al. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. 1990 Transplant. Proc. pmid:1697111
Woo J et al. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. 1990 Transplant. Proc. pmid:1697112
Woo J et al. Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis. 1990 Transplant. Proc. pmid:1697113
Propper DJ et al. Low-dose FK 506 inhibits sensitisation after blood transfusions. 1990 Transplant. Proc. pmid:1697114
Tiebosch A et al. Side effects of FK 506 in cynomolgus monkeys: a histopathologic study. 1990 Transplant. Proc. pmid:1697115
Dammeijer PF et al. Combined effect of low-dose FK 506 and cyclosporine A on skin graft survival. 1990 Transplant. Proc. pmid:1697116
Imai K et al. Pancreaticoduodenal allotransplantation with the use of FK 506, cyclosporine, and triple-regimen immunosuppression. 1990 Transplant. Proc. pmid:1697117
Iga C et al. Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin. 1990 Transplant. Proc. pmid:1697118
Deguchi K et al. [Effects of novel immunosuppressant FK 506 in acute experimental allergic encephalomyelitis]. 1990 No To Shinkei pmid:1697182
Murase N et al. Prevention of spontaneous diabetes in BB rats with FK 506. 1990 Lancet pmid:1697397
Justice RM et al. The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. 1990 Biochem. Biophys. Res. Commun. pmid:1697463
Kawashima H and Mochizuki M Effects of a new immunosuppressive agent, FK 506, on the efferent limb of the immune responses. 1990 Exp. Eye Res. pmid:1701148
Siekierka JJ et al. The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. 1990 J. Biol. Chem. pmid:1701173
Johansson A and Möller E Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. 1990 Transplantation pmid:1701570
Reyes J et al. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. 1990 Transplantation pmid:1701571
Tsuji RF et al. Selective immunosuppression of prodigiosin 25-C and FK506 in the murine immune system. 1990 J. Antibiot. pmid:1701765
Granelli-Piperno A et al. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. 1990 J. Exp. Med. pmid:1701825
Lee KK et al. Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. 1990 Transplant. Proc. pmid:1702239
Takai K et al. Effects of FK506 on rat thymus: time-course analysis by immunoperoxidase technique and flow cytofluorometry. 1990 Clin. Exp. Immunol. pmid:1702372
Okubo Y et al. FK506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis. 1990 Clin. Exp. Immunol. pmid:1702373
Arita C et al. Inhibition by FK506 of established lesions of collagen-induced arthritis in rats. 1990 Clin. Exp. Immunol. pmid:1702374
Woo J et al. Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion. 1990 Clin. Exp. Immunol. pmid:1702375
Mattila PS et al. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. 1990 EMBO J. pmid:1702384